ONCODNA provides an update about the friendly takeover bid on INTEGRAGEN

by OncoDNA

4 years ago
IntegraGen, acquisitions, DNA, oncology

OncoDNA SA has become the first shareholder of IntegraGen SA (Paris: ALINT), holding 29.99% of the existing shares, as result of purchases of shares on the Euronext Growth market .

Agreement to file a friendly takeover bid initiated by OncoDNA on IntegraGen to acquire all outstanding shares at a price of 2.20€ per share

by OncoDNA

4 years ago
molecular tests, DNA sequencing, genomic, oncology, OncoDNA, IntegraGen

This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of both c...

Boehringer acquires Northern Biologics preclinical oncology pipeline

by CataloniaBio

4 years ago
immunology, oncology, Boehringer, Northern Biologics

Boehringer Ingelheim has acquired two preclinical antibodies from Canadian firm Northern Biologics with the aim of further strengthening its global position in cancer immunology.

2019 independent nationwide evaluation ranks Vall d’Hebron’s Medical Oncology Department top of the leaderboard for sixth consecutive year

by Vall d’Hebron

4 years ago
oncology, Vall d’Hebron, MRS

Clinical trial design in the era of precision oncology: a rapidly evolving landscape

by VHIO

5 years ago
clinical trials, oncology, Cancer, biomarkers, drug development

In our collective efforts to solve cancer sooner, tumor diversity represents one of the major challenges in more effectively targeting the specificities of individual cancers. Much progress has howe...

ZeClinics joins the drug discovery and delivery network for oncology and eye therapeutics (3D-NEONET)

by ZeClinics

7 years ago
drug discovery, oncology, ophthalmology

The consortium is bringing together a unique group of microbiologists, cancer biologists, chemists, material scientists, mechanical engineers, ocular pharmacologists, geneticists and toxicologists fro...